Abstract
Introduction:
We investigated the potential hepatotoxicity of lopinavir/ritonavir recently used in the treatment of Severe Acute Respiratory Syndrome Coronavirus.
Methods:
This is a retrospective cohort of critical patients in a teaching hospital: 12 treated with lopinavir/ritonavir and 30 in the standard-of-care group.
Results:
Elevation occurred more frequently in patients treated with lopinavir/ritonavir (33% vs 6.7%).
Discussion:
Caution is advised regarding the use of lopinavir/ritonavir in the most severe cases of Severe Acute Respiratory Syndrome Coronavirus.
MeSH terms
-
Aged
-
Antiviral Agents / adverse effects*
-
Betacoronavirus / isolation & purification
-
COVID-19
-
COVID-19 Drug Treatment
-
Coronavirus Infections / complications
-
Coronavirus Infections / diagnosis
-
Coronavirus Infections / drug therapy*
-
Coronavirus Infections / virology
-
Dose-Response Relationship, Drug
-
Drug Administration Schedule
-
Drug Combinations
-
Female
-
Humans
-
Intensive Care Units / statistics & numerical data
-
Jaundice / chemically induced*
-
Jaundice / diagnosis
-
Jaundice / epidemiology
-
Lopinavir / administration & dosage
-
Lopinavir / adverse effects*
-
Male
-
Middle Aged
-
Pandemics
-
Pneumonia, Viral / diagnosis
-
Pneumonia, Viral / drug therapy*
-
Pneumonia, Viral / virology
-
Prospective Studies
-
Retrospective Studies
-
Ritonavir / administration & dosage
-
Ritonavir / adverse effects*
-
SARS-CoV-2
-
Severity of Illness Index
-
Standard of Care / statistics & numerical data
Substances
-
Antiviral Agents
-
Drug Combinations
-
lopinavir-ritonavir drug combination
-
Lopinavir
-
Ritonavir